United States Intranasal Drug Delivery Market to Reach $20.7 Billion by 2031, Growing at 8.0% CAGR

Market Size and Growth

Global Intranasal Drug Delivery Market reached US$ 11.2 billion in 2023 and is expected to reach US$ 20.7 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/intranasal-drug-delivery-market?juli

USA: Recent Industry Developments

✅ October 2025: ARS Pharmaceuticals launched its FDA-approved epinephrine nasal spray for emergency treatment of allergic reactions. The initiative offers a needle-free delivery system and aims to improve patient access to life-saving treatments.

✅ September 2025: AptarGroup rolled out its advanced nasal spray device platform to support new intranasal drugs. The system enhances dosing accuracy and patient convenience, accelerating adoption in clinical and commercial settings.

✅ August 2025: The U.S. government committed funding for clinical trials of nasal vaccines, focusing on COVID-19 and other respiratory illnesses. The program supports R&D efforts and encourages rapid development of intranasal therapies.

✅ July 2025: Several U.S. biotech firms initiated collaborations to develop intranasal formulations for central nervous system and pain management therapies. The partnerships aim to expand therapeutic applications and improve patient outcomes.

Japan: Recent Industry Developments

✅ October 2025: Takeda Pharmaceutical expanded clinical programs for intranasal therapies targeting neurological disorders. The initiative includes personalized dosing and patient support services to improve treatment effectiveness.

✅ September 2025: St. Luke's International Hospital launched intranasal treatment programs for respiratory and allergy-related conditions. The services offer patient education and multilingual support, strengthening Japan's position in advanced nasal therapies.

✅ August 2025: Keio University Hospital introduced a digital pre-consultation platform for intranasal drug patients, enabling virtual assessments and treatment planning. The platform enhances accessibility and patient engagement.

✅ July 2025: National Center for Global Health and Medicine developed intranasal vaccine pilot programs with integrated patient support services. The initiative targets both domestic and international patients, improving clinical trial participation and treatment outcomes.

Market Segmentation

1. By Type
Nasal Spray: Most widely used; preferred for rapid onset and convenience.
Nasal Drops: Suitable for localized treatment; common in pediatric use.
Nasal Gel: Provides sustained release and improved mucosal adhesion.
Nasal Powder: Dry formulation; often used for vaccines and certain CNS therapies.

2. By Container Type
Pressurized Container: Metered-dose sprays with consistent dosing; widely adopted in commercial products.
Non-pressurized Container: Manual or dropper-based; simpler and cost-effective for hospital and home use.

3. By Application
Allergic and Non-allergic Rhinitis: Leading segment due to prevalence of seasonal and perennial allergies.
Nasal Congestion: Fast-acting formulations targeting symptom relief.
Sinusitis: Both acute and chronic sinus management using intranasal steroids or saline.

Asthma: Intranasal therapy as adjunct treatment for respiratory conditions.
Others: Includes CNS disorders, pain management, migraine treatment, vaccines, and innovative therapies.

4. By Distribution Channel
Hospital Pharmacies: Preferred for prescription-based intranasal drugs and specialized treatments.

Retail Pharmacies: Major channel for over-the-counter sprays, drops, and gels.
Online Pharmacies: Growing rapidly due to convenience, especially in urban and tech-savvy populations.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=intranasal-drug-delivery-market

Key Players

AstraZeneca plc: Recognized as a major pharmaceutical company with global scale; involved in nasal‐drug/formulation research and delivery technologies.

Baxter International, Inc.: While historically strong in medical devices and therapies (notably infusion and renal), its inclusion suggests a role in nasal delivery or device/packaging interfaces for intranasal drugs.

Becton, Dickinson & Company (BD): Strong in medical devices and injectable systems; its relevance in nasal delivery likely stems from its device/packaging infrastructure and distribution channels.

GlaxoSmithKline plc (GSK): A big pharma with strong R&D in alternative delivery systems; nasal applications (allergy, respiratory) align with their therapeutic focus.

Johnson & Johnson: A diversified healthcare company; involvement in nasal delivery devices or formulations leverages their broader portfolio in consumer/med‐tech and pharma.

Novartis AG: With a large‐scale global footprint, and portfolio across multiple therapeutic areas, Novartis's inclusion shows the intranasal route is increasingly relevant beyond just allergy/respiratory.

Pfizer Inc.: A global pharma giant; its presence here likely reflects both drug formulation innovation and delivery system partnerships or acquisitions in the intranasal domain.

Valeant Pharmaceuticals International, Inc.
(Note: Valeant has since changed its name to Bausch + Lomb in many parts) Its inclusion signals that smaller/mid‐sized players focused on niche therapies and delivery routes matter in this market.

Merck & Co., Inc.: Another major pharma; its involvement emphasizes the route's relevance for serious therapies (perhaps vaccines, CNS drugs) rather than just OTC sprays.

Aegis Therapeutics LLC: A more specialised player; its presence indicates that emerging/specialty firms are also innovating in intranasal delivery, which means the market is not purely dominated by the giant pharmas.

Regional Overview

North America
Leads globally with 44.5% of revenue in 2024.
The U.S. alone accounts for 82% of the region's share.
Key drivers: advanced healthcare infrastructure, high prevalence of respiratory/CNS disorders, strong regulatory and R&D ecosystem.
Devices segment is significant, with high adoption of metered-dose sprays and innovative delivery systems.

Europe
Holds around 28-30% of the market share.
Growth supported by strong regulatory frameworks, aging populations, and rising prevalence of allergy and respiratory diseases.
Leading countries include Germany, UK, and France with strong R&D and hospital adoption of intranasal therapies.

Asia Pacific (APAC)
Fastest-growing region with a projected CAGR of 7.2%.
Holds 20-25% of the total market share.
Growth drivers: large populations (China, India, Japan), rising healthcare access, government support for non-invasive therapies and vaccines, and expanding domestic manufacturing of delivery devices.

Latin America & Middle East & Africa (MEA)
Smaller market shares (5-10%) but significant growth potential.
Growth driven by healthcare modernization, rising chronic and respiratory disease prevalence, and increasing interest in advanced drug-delivery formats.

Get Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/intranasal-drug-delivery-market?juli

Conclusion

The global intranasal drug delivery market is poised for robust growth over the coming decade, driven by the rising preference for non-invasive administration, technological innovations in formulations and delivery devices, and expanding therapeutic applications beyond traditional allergy and respiratory treatments. North America currently dominates the market, while Asia Pacific is emerging as the fastest-growing region, offering significant opportunities for expansion.
Key players, including both large pharmaceutical companies and specialized device manufacturers, are investing in R&D, partnerships, and market expansion strategies to capture the growing demand. With increasing prevalence of respiratory and neurological disorders, combined with favorable regulatory support and government initiatives for intranasal therapies and vaccines, the market is well-positioned for continued innovation and adoption.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?jk

Related Reports:
Nasal Drug Market: https://www.datamintelligence.com/download-sample/nasal-drug-delivery-systems-market?juli
Implantable Drug Market: https://www.datamintelligence.com/download-sample/implantable-drug-delivery-devices-market?juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.